MP52-12 COMPARISON OF ALTERNATIVE ANDROGEN RECEPTOR-AXIS-TARGETED AGENT (ARATA) VERSUS DOCETAXEL AS SECOND-LINE THERAPY FOR PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROGRESSING AFTER INITIAL ARATA IN REAL-WORLD CLINICAL PRACTICE IN JAPAN
Author(s) -
Yuto Matsushita,
Keita Tamura,
Takayuki Sugiyama,
Hideaki Miyake
Publication year - 2018
Publication title -
the journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.402
H-Index - 256
eISSN - 1527-3792
pISSN - 0022-5347
DOI - 10.1016/j.juro.2018.02.1663
Subject(s) - enzalutamide , docetaxel , prostate cancer , medicine , abiraterone acetate , oncology , androgen receptor , cancer , pharmacology , androgen deprivation therapy
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom